The Cancer Register (CR) in Sweden has reported that the incidence of primary liver cancer (PLC) has slowly declined over the last decades. Even though all cancers, irrespective of diagnostic method, should be reported to the CR, the PLC incidence may not reflect the true rate. Improved diagnostic tools have enabled diagnosis of hepatocellular carcinoma based on noninvasive methods without histological verification, possibly associated with missed cancer reports or misclassification in the CR. Our objective was to study the completeness and assess the underreporting of PLC to the CR and to produce a more accurate estimate based on three registers. The CR, the Cause of Death Register, and the Patient Register were investigated. Differences and overlap were examined, the incidence was estimated by merging data from the registers, and the number reported to none of the registers was estimated using a log-linear capture-recapture model. The results show that 98% of the PLCs reported to the CR were histologically verified; 80% were hepatocellular carcinoma and 20% were intrahepatic cholangiocarcinoma. Unspecified liver cancer decreased over time and constituted <10% of all reported liver cancers. The CR may underestimate the liver cancer incidence by 37%-45%, primarily due to missed cancer reports. The estimated annual number of liver cancers increased over time, but the standardized incidence was stable around 11 per 100,000. Hepatitis C-associated liver cancer increased and constituted 20% in 2010. Conclusion: There was an underreporting of PLC diagnosed by noninvasive methods; the incidence was considerably higher than estimated by the CR, with a stable incidence over time; reporting needs to improve and combining registers is recommended when studying incidence. (HEPATOLOGY 2017;65:885-892).
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P rimary liver cancer (PLC) is reported to be the fifth most common neoplasm and the second most frequent cause of cancer mortality worldwide. (1) This includes predominantly hepatocellular carcinoma (HCC) but also intrahepatic cholangiocarcinoma (ICC). In Asia and sub-Saharan Africa the dominant risk factor for HCC is chronic hepatitis B virus infection in combination with exposure to aflatoxins. In other parts of the world, such as Egypt, Japan, North America, and Europe, chronic hepatitis C virus (HCV) infection and alcohol are considered the main risk factors. (2) In most Western countries the temporal trends show an increasing incidence of HCC, probably as a result of the HCV epidemic. In Sweden, HCV prevalence is approximately 0.5% but about 1% in the population born in the 1950s and 1960s, with a high proportion infected since the 1970s and now at risk for cirrhosis and HCC. (3) Abbreviations: CR, Swedish Cancer Register; DR, Cause of Death Register; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICC, intrahepatic cholangiocarcinoma; ICD, International Statistical Classification of Diseases and Related Health Problems; LCa, all liver cancers; LCa UNS, liver cancer unspecified; PLC, primary liver cancer; PR, National Patient Register.
Yet, the HCC incidence in Sweden is reported to be low compared with other Western countries; and according to the Swedish Cancer Register (CR), the incidence of PLC and HCC has slowly decreased over the last 30 years. (4) Our hypothesis is that the low and apparently declining incidence in Sweden is due to underreporting of HCC. The CR is considered to have good data quality and high completeness and accepts clinical diagnoses as the basis for classification, but cancers without histological confirmation are less likely to be reported. (4, 5) With improved diagnostic tools identifying suspected tumors at an earlier stage and using noninvasive methods (computed tomography or magnetic resonance imaging) to verify the HCC diagnosis, (6) the risk of underreporting or classification of HCC as liver cancer unspecified (LCa UNS) may increase. Also, a decrease in the number of autopsies performed (50% in 1970 and 12% in 2010) may result in missed HCC diagnoses. (4, 7) In Sweden, there are no cross-reports between the CR and the Cause of Death Register (DR) or the National Patient Register (PR).
The aims of this project were (1) to examine the completeness of the CR regarding PLC and HCC, (2) to investigate if the low and declining incidence of PLC and HCC represents a true decrease or is a result of underreporting, and (3) to produce a more accurate estimate of the incidence of PLC in Sweden. A secondary objective was to investigate whether a capturerecapture model can be used to reliably estimate the number of cancers not reported to any of the registers.
Patients and Methods

DATA SOURCES
Every resident in Sweden has a unique 12-digit personal identification number assigned at birth or immigration and used in all health care contacts and in all national registers. In this study the personal identification number was used to link personal data in several national registers, the CR, DR, and PR at the National Board of Health and Welfare (8) and the hepatitis C surveillance register at the Public Health Agency of Sweden. (9) After the linkage procedure, all personal identification numbers were replaced by sequential numbers to produce an anonymous data file.
The Swedish CR was founded in 1958. (8) It is compulsory for every health care provider to report newly detected cancer diagnoses to the register. A report has to be sent for every cancer diagnosed by clinical, morphological, or other laboratory examinations as well as diagnoses at autopsy, often resulting in multiple reports merged into one in the CR. The basis for diagnosis is recorded. The Swedish CR does not use information from death certificates or diagnoses in the DR or PR.
The DR includes all deaths among Swedish residents and relies on information from death certificates (missing in only 1%-2% of deaths). In the DR the date and cause of death (underlying and contributory) and the basis for the diagnosis are recorded.
In the 1960s the PR began collecting information on inpatient admissions at public hospitals. Participation has been mandatory since 1984 for all county councils, and from 1987 the PR has included all inpatient care in Sweden. Every inpatient episode is recorded with dates and diagnoses at discharge, and the validity has been reported to be high. (10) Since 2001 the PR also includes outpatient data, but only inpatients were included in this study.
Diagnoses in these registers are coded according to the International Statistical Classification of Diseases and Related Health Problems (ICD). Since 2005 the cancer diagnoses in the CR have been coded according to the
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third version of the International Classification of Diseases for Oncology, but all diagnoses are also available in the second version since 1993 and as ICD-7 codes from 1958. The official annual report "Cancer Incidence in Sweden" still uses the ICD-7 coding, which does not differentiate between HCC and ICC. (4) To identify patients with liver cancer (LCa) in the CR, the ICD-7 codes for PLC (155.0) and LCa UNS (156) were used. The second version of the International Classification of Diseases for Oncology was used to differentiate between HCC (C22.0), ICC (C22.1), and LCa UNS (C22.9) in the CR for the period 1993-2011.
The diagnoses in the PR and DR were classified according to ICD-8 in 1968 ICD-8 in -1986 , ICD-9 in 1987-1996, and ICD-10 from 1997. In this study, PR and DR data were limited to 1997-2012 to only use ICD-10. The codes corresponding to those in the CR were used, that is, C22, including HCC (C22.0), ICC (C22.1), LCa UNS (C22.9), and a few other liver tumors (C22.2-C22.7). The Swedish DR relies only on information from death certificates, and from 1997 (introduction of ICD-10) the code C22.0 (HCC) was used only when the physician had stated clearly "hepatocellular carcinoma" on the death certificate. The more common "primary liver cancer" or "liver cancer" (predominantly HCC) was coded C22.9 during 1997-1999, and from year 2000 the death certificate diagnosis "primary liver cancer" was classified as C22.90 and "liver cancer" as C22.99. Secondary tumors (metastases) have other ICD codes and were not included.
Since 1990, hepatitis C has been a notifiable disease in Sweden. All laboratories report first-time positive anti-HCV tests, and physicians report newly diagnosed infections to the register of communicable disease at the Public Health Agency of Sweden. (11) In this study the HCV register was used to identify HCV-infected individuals in the study population.
STUDY POPULATION AND DESCRIPTIVE STATISTICS
Incidence data were retrieved from the CR for the period 1970-2013 to show change in PLC incidence over time. In the CR, all individuals reported with PLC or LCa UNS from 1975 until the end of 2011 were identified, and the basis for diagnoses was investigated. For the time period 1993-2011 the annual numbers of HCC, ICC, and LCa UNS were determined.
To study the completeness of the CR and estimate incidence, all individuals with a PLC diagnosis in the CR (up to 2011), PR, and DR (up to 2012) were identified. In addition, the ICD codes for LCa UNS were included because of the hypothesis that the use of noninvasive diagnostic methods may result in more reports of LCa UNS and because the DR uses these codes for PLC (mostly HCC). The study period for the crosschecking and modeling was limited to 1997-2012 to only use ICD-10 codes in the PR and DR and avoid changes in the ICD classification. In the following we use the abbreviation "LCa" for the liver cancers studied when combining the registers.
The mortality from LCa is high, but not all patients have died. Most patients with LCa have been inpatients, but some have not and are consequently not recorded in the DR or the PR, respectively. However, all patients with LCa diagnoses in the DR and PR should have been reported to the CR following the diagnostic examination. For those missing in the CR, we investigated if they were registered in the CR for another cancer diagnosis, to assess if the LCa diagnoses in the DR or PR may be attributed to misclassification of other cancers with liver metastases.
Venn diagrams, with areas proportional to degree of overlap, were constructed to graphically present how the different registers relate to each other for LCa. For comparative purposes, Venn diagrams were also produced for malignant lymphoma and colon cancer, cancers that are more often diagnosed using biopsies/cytology.
A previous study demonstrated the increased risk of HCC in the cohort of HCV-infected individuals in Sweden. (12) To further examine this and interpret the results of our study, we analyzed the proportion of patients with LCa who were also notified for HCV infection.
Standardized incidence rates based on the combined number of LCa diagnoses in the three registers for the time period 1998-2011 were calculated to further investigate changes in LCa incidence over time.
STATISTICAL MODELING METHODS
For the modelling of a more accurate incidence, using data from the time period 1997-2012, each patient was assigned an "index" year, defined as the first year the patient was recorded with LCa in any of the three registers. Only index years up to 2010 were used; inclusion of later index years could give an erroneously high number of patients captured in only one or two registers because of too short follow-up. Also, to avoid edge effects related to the change of ICD codes in the PR and DR, 1997 as index year was excluded from modeling. Linkage between registers was used to identify patients reported to more than one register. For all modeling, patients with LCa in the PR and/or DR who were not reported to the CR with LCa but with other cancer diagnoses were removed.
For patients with their index year during 1998-2010, the total number of LCa diagnoses was calculated as the sum of unique patients reported with LCa in the CR only (model A) and in the CR, DR, and PR combined, accounting for overlaps (model B). For a more accurate incidence, the estimated number of individuals with LCa not recorded in any of the three registers was added to the sum of patients with LCa in the CR, DR, and PR combined, accounting for overlaps (model C). To estimate the number of individuals missing in all three registers, a log-linear capture-recapture model was used. (13) The model was parameterized, with one parameter for each register (data source), one interaction term for the two most overlapping registers (the DR and the PR), and a three-way interaction term. As a sensitivity analysis and to create a lower bound for the true incidence, a two-source model joining the DR and the PR was created (model D). The models are described in more detail in Supporting Table S1 .
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Results
DESCRIPTIVE DATA
The reported incidence of LCa in the CR has decreased over time during 1970-2013, as shown in Fig. 1 (standardized according to the population year  2000) .
In the CR during 1975-2011 there were a total of 21,038 individuals reported to have LCa, of whom 16,380 were classified as PLC (ICD-7 155.0) and another 4,658 as LCa UNS (ICD-7 156) . The basis for LCa diagnosis reported to the CR has changed over time (Fig. 2) ; in the 1970s 65%-70% of cases were based on autopsy with histological verification, but more recently this has fallen to less than 10%. On the other hand, diagnosis by biopsy/operation with histology has increased from 20% in the 1970s to 65%-70% in more recent years, but diagnosis by noninvasive methods was rare in the CR. The results show that 98% of PLCs in the CR were histologically verified; approximately 80% were HCC and 20% ICC. Over time, the number of LCa UNS decreased to <10% of all LCa (Fig. 3) .
For patients with their index year between 1998 and 2010, there were 6,439 diagnosed with LCa in the CR and 8,860 diagnosed with LCa in the DR, either as the underlying cause of death or as a contributory cause of death. In the PR there were 9,464 patients admitted to hospital for LCa during the same period. Altogether there were 13,749 individuals with LCa diagnosis recorded in at least one of the registers, and 47% of these cancers were reported to the CR, 69% were reported to the PR, and 64% were reported to the DR. The distribution of incident LCa across the registers is shown as a Venn diagram (Fig. 4, left panel) . Overlap between all three registers is large, but there are also a large number of cancers captured only in the PR and the DR, where there is the largest overlap. In comparison, colon cancer and lymphoma (Fig. 4) show the largest overlap between the PR and the CR. For colon cancer and lymphoma, 80% and 82%, respectively, of all reported cancers (CR, PR, and DR together) were reported to the CR.
ESTIMATING THE NUMBER OF LCa DIAGNOSES 1998-2010
Out of the 13,749 patients recorded with an LCa diagnosis in any of the three registers during the index years 1998-2010, 7,310 were not in the CR with an LCa diagnosis, and 3,762 of these were not registered in the CR at all. However, 3,548 of these 7,310 patients were recorded in the CR with another cancer diagnosis. For the estimation of the number of LCa diagnoses, these 3,548 patients were excluded from further calculations and modeling, even though some of them likely were true LCa. This was to avoid bias associated with erroneous recording of other cancers as LCa in the DR and PR, to ensure a conservative approach and rather present slight underestimations instead of inflated numbers. This reduced the total number of LCas to 10,201 (for the three registers combined), used to estimate a more accurate incidence of LCa.
In Fig. 5 , the annual number of LCas in the CR (model A), the annual number of LCas from the three registers combined (model B), and the annual number of LCas including those estimated from the capturerecapture model (models C and D) are shown. Based on log-linear modeling, the estimated number of LCas not reported to any of the three registers is between 8% and 13% of the total number of LCa diagnoses in the three registers, the lower number being an estimated lower bound for the true incidence (model D). The completeness of the CR is estimated to be 55%-67% depending on the assumptions for modeling the unreported cancer diagnoses (Supporting Table S1 ).
The temporal trend in reported numbers of LCa in the CR is relatively flat at around 500 cases a year during 1993-2011 (Fig. 3) , with a rising tendency the last years. The total number of LCas present in any of the three registers increased slightly over this time period, from about 1,000 to around 1,100 (Fig. 5) . Calculation of standardized incidence rates shows that this increase is likely attributable to an aging and growing population and does not reflect a true increase in the incidence of liver cancer. The annual incidence of LCa calculated in this way was stable at around 11 diagnoses per 100,000.
HCV INFECTION IN PATIENTS WITH LCa
The proportion of patients notified with an HCV diagnosis among all patients reported with LCa increased from about 5% in 1998 to approximately 20% in 2010. The proportion of patients with a confirmed HCV diagnosis was similar among patients reported to the three different registers, including LCa patients never reported to the CR.
Discussion
This study indicates that the incidence of LCa in Sweden is much higher than that reported by the national CR and that the standardized incidence is stable and not decreasing. Combining the CR, DR, and PR demonstrated a considerable degree of underreporting, the LCa in the CR constituted roughly 50% of the total number of LCa cases reported in the three registers together. This was 63% when excluding patients reported with another cancer diagnosis in the CR. Still, a large proportion of patients with LCa diagnoses were not reported to the CR at all. As demonstrated, it is likely that the missing reports included HCCs diagnosed by noninvasive methods, but further studies to investigate the reason for underreporting are needed.
In Sweden it is mandatory to report diagnosed cancers to the CR, both for physicians clinically working and for pathology laboratories. The laboratories have implemented reporting procedures with high completeness. This is not the same for clinicians, but a laboratory report usually includes a reminder to the clinician. In the last decade, noninvasive diagnostic methods based on imaging technologies have been recommended for HCC diagnosis, (6) and with no histology report from the laboratory, the LCa might not be reported to the CR. This hypothesis is supported by (1) the high percentage of histological verification and the low proportion of LCa diagnoses based on noninvasive methods in the CR; (2) no increase of LCa UNS in the CR; (3) the increasing number of LCa diagnoses reported to the PR but not the CR (data not shown); and (4) the finding of a stable LCa incidence in this study in contrast to the decrease reported by the CR. Also, the same analyses were performed for colon cancer and lymphoma and demonstrated a much higher concordance between registers. For   FIG. 4 . Venn diagrams depicting number of cancers reported to the CR, PR, and DR for LCa, colon cancer, and lymphoma. Areas adjusted to illustrate number of reported cases for different registers and combination of registers. these cancers it is more likely that the CR reflects the true incidence. The basis for diagnosis of LCa reported to the CR has changed (Fig. 2) . In the 1970s almost 70% were diagnosed at autopsy and histologically verified; in contrast, in recent years almost all diagnoses were in living patients, 70% with percutaneous biopsy or biopsy during surgery and another 15%-20% with cytology. Among those who died from LCa, <10% had an autopsy. Since the 1970s the number of autopsies in Sweden has declined from >50% to 12%. This may be a result of improved imaging technologies detecting tumors at an earlier stage, before the patient dies; but the decline in autopsy rate may also result in missed LCa diagnoses. (7) In many Western countries the incidence of HCC is increasing as a result of the HCV epidemic. In our study, the proportion of LCa patients with HCV diagnosis increased from 5% in 1998 to about 20% in 2010. This demonstrates that HCV is an important cause of HCC also in Sweden, although an increase of the standardized incidence has not yet been demonstrated. The proportion of HCV among patients with LCa was almost identical for all three registers, evenly distributed, indicating that LCa patients with HCV are not more likely to be reported to the CR compared to patients without HCV infection. The proportion of patients with HCV in the registers may serve as a proxy to compare registers with regard to degree of misclassification, assuming that patients with HCV and LCa diagnoses to a higher degree represent true HCC. The results indicate that the degree of misclassification is not larger in the DR and PR compared to the CR.
The quality of the CR is generally considered to be very high. A quality study of the CR estimated the underreporting at approximately 4%; the degree of underreporting was dependent on the cancer site and increased with age, and diagnoses without histology or cytology were particularly likely to be unreported. (5) We found that for LCa the completeness of the CR was low. Studies of pancreatic cancer in Sweden have made similar findings and conclusions. (14) (15) (16) In another study in Sweden, all patients who died in 1999-2008 with cancer as the underlying cause of death were identified and linked to the CR and PR. (17) In total, 79.8% were found in the CR with concordant cancer and 9.6% with a discordant cancer. The missing identification depended on tumor site and age at death and was highest among individuals who died of cancers in the liver, pancreas, and kidney.
Our findings are in line with a recent Australian study estimating the HCC incidence in Melbourne to be 2-fold higher than reported by CR data, (18) but there are some important differences. Misclassification was a major explanation in the Australian study, only HCC cases with histological verification were classified as HCC (138 in 1 year), the HCCs diagnosed by noninvasive methods and reported to the CR were classified as LCa UNS (123/162 LCa UNS), but about 25% of HCCs were not reported at all. In the Swedish CR we found that 98% of the cancers classified as PLCs (80% HCC and 20% ICC) were histologically verified, but the number of LCa UNS was very small and decreasing, constituting <10% of all LCa cases (Fig. 3) . Noninvasive methods for HCC diagnosis (6) have not increased the classification of HCCs as LCa UNS, indicating that in Sweden noninvasive diagnosis is followed by missed cancer reports rather than misclassification. Another difference is study design: the Australian study tried to identify all HCCs during 1 year by searching different sources, whereas our study used national registers to find HCC, ICC, and LCa UNS from 1975 and forward to study temporal trends and make a model for the estimation of more accurate incidences.
A limitation with this type of study may be the quality of the ICD coding. When estimating changes in HCC or LCa incidence over time it is necessary to consider changes in ICD coding systems and possibilities for misclassification. A change of the version of ICD codes or in coding policies may influence official reports or epidemiological studies, for example, the change of coding policies for HCC/LCa in the DR. (19) For the capture-recapture estimation, the ICD codes need to select the same diagnoses in the three registers. In this study a restriction to only HCC codes would produce inaccurate estimates. The ICD codes in this study were chosen to select all PLCs (HCC and ICC) with histological verification and those without, possibly misclassified as LCa UNS. This was important because of the hypothesis that HCCs were misclassified or not reported at all. To avoid an inflated estimate and to rather underestimate the total number, all patients with LCa reported only to the PR and/or DR but with other cancer diagnoses in the CR (n 5 3,548) were removed from the data set, and all estimations were based on this reduced data set.
A secondary aim was to investigate the usefulness of a capture-recapture model in estimating the number of cancers not reported by any of the registers. Our study shows that there are modeling options based on three HEPATOLOGY, Vol. 65, No. 3, 2017 T € ORNER ET AL.
sources that can take into account two-way and threeway interactions despite some data limitations. The advantage of the proposed model over other models in the literature is that there is no assumption of a zero three-way interaction, which may be a major assumption that cannot be readily verified (see Supporting Information). These results reflect the situation in Sweden, a country with well-organized registers considered to have high reliability. The situation may be the same in other countries with a national CR, but the policies for coding and cross-linking between registers may differ. In studies of relative risk comparing CR data in one cohort with CR data in another population, incomplete data may not influence the results. However, when reporting national incidences and temporal trends or when studying HCC or PLC incidence based on CR data, the risk of underreporting or misclassification must be considered. When possible, additional data from death and/or patient registers could be a complement.
To conclude, this study indicates that 37%-45% of LCas in Sweden were never reported to the CR, and this percentage has increased slightly over time. Improved diagnostic methods with the possibility of noninvasive diagnosis may result in underreporting or misclassification. These findings should be considered in official reports or studies of HCC incidence based on CR data. Linkage of multiple registers and capturerecapture models may be useful to model the number of cancers not reported at all and thereby estimate the total number. We recommend that efforts should be made to improve the reporting procedures for cancers diagnosed with noninvasive methods.
